Bioventix plc (BVXP) Ordinary 5p

Sell:2,950.00pBuy:3,050.00pNo change

FTSE AIM 100:0.42%
Market closed | Prices delayed by at least 15 minutes
Sell:2,950.00p
Buy:3,050.00p
Change:No change
Market closed | Prices delayed by at least 15 minutes
Sell:2,950.00p
Buy:3,050.00p
Change:No change
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.

Key people

Peter Harrison
Chief Executive Officer, Executive Director
Bruce Edward Heath Hiscock
Chief Financial Officer, Executive Director
Ian James Nicholson
Independent Non-Executive Chairman of the Board
Joanne Pisani
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    BVXP
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00B4QVDF07
  • Market cap
    £156.59m
  • Employees
    17
  • Shares in issue
    5.22m
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.